

Drug Monograph

Drug/Drug Class: **Doryx[®] (doxycycline) Delayed-Release Tablet / Antibiotic**

Prepared for: MO HealthNet

Prepared by: Xerox Heritage, LLC

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Each Doryx [®] 150 mg and 200 mg delayed release tablet contains doxycycline 150 mg and 200 mg doxycycline respectively.
Manufacturer:	Mayne Pharma International Pty Ltd. Salisbury South, SA 5106 Australia Warner Chilcott (US), LLC Rockaway, NJ 07866
Indications:	Doryx [®] is indicated for the treatment of <i>Rickettsial</i> infections; sexually transmitted infections caused by <i>Ureaplasma urealyticum</i> , <i>Chlamydia trachomatis</i> , <i>Calymmatobacterium granulomatis</i> , <i>Neisseria gonorrhoeae</i> , and <i>Haemophilus ducreyi</i> ; respiratory tract infections caused by <i>Mycoplasma pneumonia</i> and <i>Chlamydophila psittaci</i> ; ophthalmic infections caused by <i>Chlamydia trachomatis</i> ; anthrax; several specific bacterial infections caused by uncommon organisms including <i>Borrelia recurrentis</i> , <i>Ureaplasma urealyticum</i> , <i>Haemophilus ducreyi</i> , <i>Yersinia pestis</i> , <i>Francisella tularensis</i> , <i>Vibrio cholerae</i> , <i>Campylobacter fetus</i> , <i>Brucella spp</i> , <i>Bartonella bacilliformis</i> , and <i>Klebsiella granulomatis</i> ; malaria prophylaxis; and as an adjunct treatment for severe acne.
Costs:	\$18.42 per tablet of Doryx [®] 150 mg and \$25.46 per tablet of Doryx [®] 200 mg. WAC
Summary of Findings:	The Division recommends this product be considered for inclusion in the state specific Preferred Drug List as a non-preferred product.
Status Recommendation:	<input type="checkbox"/> Prior Authorization (PA) Required <input type="checkbox"/> Open Access <input type="checkbox"/> Fiscal Edit <input checked="" type="checkbox"/> PDL
Type of PA Criteria:	<input type="checkbox"/> Increased Risk of ADE <input checked="" type="checkbox"/> Non-Preferred Agent <input type="checkbox"/> Appropriate Indications <input type="checkbox"/> Under Solicitation

Prepared By: Chelsea Ames, Pharm.D. Candidate

Date: August 2, 2013